Canonical owner for the ASCVD/Lp(a) prevention logic. Lp(a) 838.6 mg/L is the fixed genetic risk anchor and makes standard calculators understate risk; old RPPH papers add a 2024-01-22 right-leg arterial Doppler showing mild common-femoral atherosclerosis/PAD (24-31% stenosis), so the question is no longer pure risk-factor-only inference. Current management is aggressive control of modifiable risk: smoking abstinence, BP measurement/control, low ApoB/LDL, coronary/valve imaging to define burden, no self-directed aspirin while GI bleeding risk is live, and therapy-watchlist monitoring for outcomes-proven Lp(a)-specific drugs.
cardiovascular · lp(a) · ascvd · prevention-status · apob · aspirin · pcsk9 · hdl · smoking · bleeding-risk
This is the single current owner for Lp(a), prevention tier, HDL context, and aspirin/antithrombotic boundaries.
Lp(a) is the stable cardiovascular risk anchor: 838.6 mg/L (reference <250 mg/L), roughly 83.9 mg/dL by simple division but not reliably convertible to nmol/L because apo(a) isoform size and assay method matter. Preserve the raw value/unit; use nmol/L if a future lab can report it directly.
Old RPPH papers found in June 2026 document right common-femoral artery atherosclerosis / mild PAD on 2024-01-22 Doppler: mixed plaque with 24-31% CFA stenosis, thin calcified/soft plaque in SFA/popliteal artery without significant stenosis, and no distal tibioperoneal/ATA/PTA stenosis. The certificate called it an incidental finding that might not explain the hip/leg symptom, but it is still objective extracoronary atherosclerosis. Archive ID: rpph-2024-01-22-cardiology-orthopedic-papers.
Coronary and aortic-valve burden remain unknown until CAC/CCTA/echo. The prevention label should therefore avoid two errors: not “risk-factor only / no documented disease” anymore, but also not automatically post-MI secondary prevention. Treat this as documented mild peripheral atherosclerosis with unresolved coronary/valve staging.
The action is not “lower Lp(a) with lifestyle.” Lp(a) is mostly genetic. The action is: treat every modifiable risk driver harder than a standard calculator would suggest, define coronary/valve burden, and avoid adding bleeding-risk drugs without a real indication.
| Finding | Prevention interpretation | What changes |
|---|---|---|
| 2024-01-22 right-leg Doppler: mild CFA plaque/stenosis 24-31% | Documented extracoronary atherosclerosis / mild PAD signal; symptom causality uncertain | Cardiology/prevention discussion becomes more justified; coronary CAC/CCTA + echo still needed to stage heart/valve burden. Aspirin remains GI-risk individualized, not self-directed. |
| No coronary/valve imaging yet | Coronary and valve burden unknown despite mild peripheral plaque | Continue statin/ApoB control; prioritize smoking abstinence, BP profile, echo/CAC/CCTA logistics. |
| CAC = 0 | Still primary prevention; lower near-term calcified-plaque risk, not a full Lp(a) all-clear | Continue ApoB/LDL, smoking, BP, and valve vigilance. CCTA only if symptoms/specialist concern/direct plaque question justifies it. |
| CAC 1-99 | Subclinical calcified atherosclerosis | Cardiology discussion; tighten LDL/ApoB target discussion; PCSK9/ezetimibe more defensible if target not met. Aspirin still unattractive while GI bleeding risk is live. |
| CAC 100-399 | Meaningful plaque burden | Cardiology review; lower LDL/ApoB target; PCSK9 discussion; CCTA/functional testing if anatomy or symptoms would change management. |
| CAC >=400 | Severe calcified plaque burden | Specialist-directed coronary workup; screening logic ends. |
| CCTA non-obstructive plaque | Documented coronary atherosclerosis, not automatically post-MI secondary prevention | Stronger lipid/BP intensity. Aspirin individualized, not casual. |
| CCTA obstructive CAD or ischemia-producing disease | Chronic coronary disease / secondary-prevention-style management | Cardiology-led lipid, BP, antithrombotic, and follow-up plan; GI bleeding history must be part of antiplatelet choice. |
| Echo aortic sclerosis/stenosis | Lp(a)-linked target-organ disease documented, not ASCVD | Valve surveillance interval; reinforces risk-factor seriousness; no aspirin indication by itself. |
| HDL repeatedly >2.3-2.6 mmol/L | Possible high-HDL U-curve/dysfunction context | Revisit HDL workup only if repeated; current HDL 1.99 makes this monitoring-only. HDL does not neutralize Lp(a). |
| Stool blood/iron branch remains live | Bleeding cost of aspirin/antiplatelets remains high | No self-directed aspirin; disclose GI context before any antithrombotic decision. |
| Lever | Current rule |
|---|---|
| ApoB / LDL | Keep atorvastatin as lipid floor unless clinician changes it. Current ApoB about 66 mg/dL / LDL-C about 2.04 mmol/L is good, but the 2024 peripheral plaque makes a lower specialist-selected ApoB/LDL target or ezetimibe/PCSK9 discussion more defensible, especially if CAC/CCTA/echo adds coronary or valve disease. |
| Smoking | Highest-ROI modifiable ASCVD/thrombotic lever. Treat abstinence as core therapy, not lifestyle garnish. |
| Blood pressure | Major missing variable. Complete standardized 7-day upper-arm home BP profile; BP control may be as important as lipid intensification if elevated. |
| Imaging/echo | Echo for valve/LV baseline; CAC as low-friction plaque anchor; CCTA if symptoms recur, CAC is positive/meaningful, or plaque composition would change management. Detailed imaging logic lives in the imaging owner. |
| PCSK9 / ezetimibe | PCSK9 is a bridge option: strong LDL/ApoB lowering plus modest Lp(a) lowering, not Lp(a) normalization. Case is stronger with documented plaque (now mild peripheral plaque; stronger still if CAC/CCTA plaque) or specialist-selected very-low targets. Ezetimibe is LDL-lowering only. |
| Lp(a)-specific therapies | Track pelacarsen/olpasiran/muvalaplin/lepodisiran/zerlasiran outcomes, approvals, access, and price in the therapy watchlist, not by expanding this page. |
| Family screening | First-degree relatives should have Lp(a) checked once; brother appears affected, reinforcing inherited framing. |
| Avoid | Reason |
|---|---|
| Do not call this risk-factor-only anymore | The 2024 Doppler documents mild peripheral atherosclerosis/PAD; coronary and valve burden still need staging. |
| Do not treat mild PAD as automatic post-MI-style secondary prevention | It raises prevention intensity, but antiplatelet and PCSK9 decisions still require cardiology + GI-risk context. |
| Do not use HDL as reassurance | HDL 1.99 is metabolically favorable, and the old 2.53 peak is worth remembering, but HDL does not offset Lp(a), smoking, BP, or plaque uncertainty. |
| Do not restart aspirin on your own | Prior diverticular hemorrhage plus stool-blood/iron history keeps bleeding risk high; mild PAD shifts the question to cardiology + GI risk balancing, not self-treatment. |
| Do not self-start antiplatelet/anticoagulant logic after CAC/CCTA findings | If true coronary disease is documented, antithrombotic decisions become cardiology + GI risk balancing. |
| Do not chase niacin for Lp(a) | It lowers Lp(a) but failed outcome logic and side effects make it a poor routine prevention tool. |
| Do not relax risk control after CAC=0 | CAC=0 misses non-calcified plaque and says nothing about valve disease, BP, or future risk from continued smoking. |
| Do not overbuild HDL subfraction/genetic testing now | Revisit only if HDL repeatedly returns to >2.3-2.6 mmol/L or imaging shows discordant disease despite otherwise favorable lipids. |
Evidence anchors include private source abstraction rpph-2024-01-22-cardiology-orthopedic-papers; EAS/consensus Lp(a) risk evidence (PMID: 36036785; PMID: 41381044; PMID: 41899103), ACC/AHA primary prevention and aspirin limits (PMID: 30879355), chronic coronary disease / CCTA risk-tier framing (PMID: 37471501; PMID: 39210710), ESC/EAS lipid-intensification context (PMID: 41785983), aspirin/high-Lp(a) subgroup evidence and bleeding uncertainty (PMID: 18775538; PMID: 36175048; PMID: 38293935; PMID: 39191359; PMID: 30667501; PMID: 35471505), recurrent diverticular hemorrhage antiplatelet concern (PMCID: PMC6219900), and HDL U-curve/function evidence (PMID: 41618310; PMID: 41284745; PMID: 40443511; PMID: 35583863; PMID: 40858201; PMID: 41618471).